Articles related to Hematology/Oncology

A retrospective cohort of 146 adult patients with T-cell ALL treated with a pediatric-inspired regimen at a single center achieved 3-year overall survival of 73% and leukemia-free survival of 77%, with age over 60 emerging as the primary adverse prognostic factor and early T-cell precursor phenotype showing no independent survival impact.

In a retrospective VA cohort of 669 mCRPC patients who did not progress on initial docetaxel, rechallenge with docetaxel was associated with improved overall survival compared with cabazitaxel after inverse probability of treatment weighting, though short follow-up and inherent selection pressures limit interpretation.

Phase 3 ASCENT-04 data presented at ASCO 2026 showed improved PFS2 for sacituzumab govitecan plus pembrolizumab over chemotherapy plus pembrolizumab in previously untreated PD-L1-positive advanced triple-negative breast cancer, though an independent expert challenged PFS2 as a valid endpoint for establishing frontline standard-of-care status.

GLP-1 receptor agonist use was associated with a 41% lower overall risk of obesity-related cancers in a retrospective cohort of more than 229,000 non-diabetic patients with obesity, with the largest risk reductions observed in endometrial, pancreatic, colorectal, and multiple myeloma.

Long-term follow-up from the phase 3 NRG-GY018 trial showed sustained overall survival benefit for pembrolizumab plus carboplatin-paclitaxel in dMMR endometrial cancer at 48 months, while the pMMR OS advantage did not reach statistical significance despite a 9-month median improvement.

Perioperative apalutamide plus ADT, six months before and after radical prostatectomy, achieved a ninefold improvement in major pathologic response and a 20% reduction in metastasis-free survival events versus placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer in a phase 3 trial.